Compare Amgen, Inc. (AMGN) vs Nerdwallet Inc (NRDS) Price & Performance

Amgen, Inc.Trade

Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Nerdwallet Inc — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Nerdwallet Inc trades at $9.59 (market cap $623.11M). The key difference: Amgen, Inc. is far larger — about 314.7× Nerdwallet Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

	AMGN	NRDS
Market Cap	$196.12B	$623.11M
Sector	Health	Financials
52-Week High	$388.16	$15.93
52-Week Low	$271.18	$7.58
Enterprise Value	$241.41B	$537.41M
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Nerdwallet Inc

NRDS trades at $9.47, down 1.56% today, with a bullish technical signal from moving averages and strong fundamentals including a 93% gross margin and three consecutive earnings beats. Revenue grew to $837M in 2025, with net income reaching $49M. Analyst consensus is Buy with a $12.75 target, implying 35% upside. Positive news highlights the company's pivot to higher-margin transactions and launch of a Financial Resilience Index.

The outlook is positive given undervaluation (P/E 10.18, P/S 0.83) and earnings momentum, but risks include search traffic dependence and projected negative cash flow in 2026. Institutional sentiment is bullish with 66% Buy ratings, supporting a constructive view for long-term investors seeking growth at a reasonable price.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).